Similar articles

• [Immunosuppression by means of antilymphocyte serums in humans].

  Revillard JP. Revillard JP. Nouv Rev Fr Hematol. 1972 Mar-Apr;12(2):129-37. Nouv Rev Fr Hematol. 1972. PMID: 4264610 French. No abstract available.
• Use of monoclonal antibodies to T cells (OKT3) for treatment of acute cellular rejection after renal transplantation.

  Birkeland SA, Svendsen V, Rohr N, Hansen BL, Elbirk A, Foged N, Køhler F. Birkeland SA, et al. Transplant Proc. 1988 Jun;20(3):451-4. Transplant Proc. 1988. PMID: 3289183 No abstract available.
• A model of human anti-T-cell monoclonal antibody therapy in SCID mice engrafted with human peripheral blood lymphocytes.

  Tsuchida M, Brown SA, Tutt LM, Tan J, Seehafer DL, Harris JP, Xun CQ, Thompson JS. Tsuchida M, et al. Clin Transplant. 1997 Oct;11(5 Pt 2):522-8. Clin Transplant. 1997. PMID: 9361954
• Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3.

  Bonnefoy-Berard N, Revillard JP. Bonnefoy-Berard N, et al. J Heart Lung Transplant. 1996 May;15(5):435-42. J Heart Lung Transplant. 1996. PMID: 8771497 Review.
• New approaches to the use of antibodies for immunosuppression.

  Russell PS. Russell PS. Transplant Proc. 1982 Sep;14(3):506-8. Transplant Proc. 1982. PMID: 6758236 Review. No abstract available.